|
1
|
Yachida S and Iacobuzio-Donahue CA: The
pathology and genetics of metastatic pancreatic cancer. Arch Pathol
Lab Med. 133:413–422. 2009.PubMed/NCBI
|
|
2
|
Huguet F, Girard N, Guerche CS, Hennequin
C, Mornex F and Azria D: Chemoradiotherapy in the management of
locally advanced pancreatic carcinoma: A qualitative systematic
review. J Clin Oncol. 27:2269–2277. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koeffler HP: Peroxisome
proliferator-activated receptor gamma and cancers. Clin Cancer Res.
9:1–9. 2003.PubMed/NCBI
|
|
4
|
Rumi MA, Sato H, Ishihara S, Kawashima K,
Hamamoto S, Kazumori H, Okuyama T, Fukuda R, Nagasue N and
Kinoshita Y: Peroxisome proliferator-activated receptor gamma
ligand-induced growth inhibition of human hepatocellular carcinoma.
Br J Cancer. 84:1640–1647. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sasaki T, Fujimoto Y, Tsuchida A, Kawasaki
Y, Kuwada Y and Chayama K: Activation of peroxisome
proliferator-activated receptor gamma inhibits the growth of human
pancreatic cancer. Pathobiology. 69:258–265. 2001. View Article : Google Scholar
|
|
6
|
Farrow B, O'Connor KL, Hashimoto K,
Iwamura T and Evers BM: Selective activation of PPARgamma inhibits
pancreatic cancer invasion and decreases expression of tissue
plasminogen activator. Surgery. 134:206–212. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hashimoto K, Ethridge RT and Evers BM:
Peroxisome proliferator-activated receptor gamma ligand inhibits
cell growth and invasion of human pancreatic cancer cells. Int J
Gastrointest Cancer. 32:7–22. 2002. View Article : Google Scholar
|
|
8
|
Koshiba T, Hosotani R, Wada M, Fujimoto K,
Lee JU, Doi R, Arii S and Imamura M: Detection of matrix
metalloproteinase activity in human pancreatic cancer. Surg Today.
27:302–304. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bramhall SR, Neoptolemos JP, Stamp GW and
Lemoine NR: Imbalance of expression of matrix metalloproteinases
(MMPs) and tissue inhibitors of the matrix metalloproteinases
(TIMPs) in human pancreatic carcinoma. J Pathol. 182:347–355. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Farrow B and Evers BM: Activation of
PPARgamma increases PTEN expression in pancreatic cancer cells.
Biochem Biophys Res Commun. 301:50–53. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen JS, Wang Q, Fu XH, Huang XH, Chen XL,
Cao LQ, Chen LZ, Tan HX, Li W, Bi J, et al: Involvement of
PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in
hepatocellular carcinoma: Association with MMP-9. Hepatol Res.
39:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagase H and Woessner JF Jr: Matrix
metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li X, Yang Z, Song W, Zhou L, Li Q, Tao K,
Zhou J, Wang X, Zheng Z, You N, Dou K and Li H: Overexpression of
Bmi-1 contributes to the invasion and metastasis of hepatocellular
carcinoma by increasing the expression of matrix metalloproteinase
(MMP)-2, MMP-9 and vascular endothelial growth factor via the
PTEN/PI3K/Akt pathway. Int J Oncol. 43:793–802. 2013.PubMed/NCBI
|
|
14
|
Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP,
Wang SH, Liang X and Lu CX: PTEN inhibits the migration and
invasion of HepG2 cells by coordinately decreasing MMP expression
via the PI3K/Akt pathway. Oncol Rep. 23:1593–600. 2010.PubMed/NCBI
|
|
15
|
Goggins M: Molecular markers of early
pancreatic cancer. J Clin Oncol. 23:4524–4531. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Michalik L, Desvergne B and Wahli W:
Peroxisome-proliferator-activated receptors and cancers: Complex
stories. Nat Rev Cancer. 4:61–70. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kristiansen G, Jacob J, Buckendahl AC,
Grützmann R, Alldinger I, Sipos B, Klöppel G, Bahra M, Langrehr JM,
Neuhaus P, et al: Peroxisome proliferator-activated receptor gamma
is highly expressed in pancreatic cancer and is associated with
shorter overall survival times. Clin Cancer Res. 12:6444–6451.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Toyota M, Miyazaki Y, Kitamura S, Nagasawa
Y, Kiyohara T, Shinomura Y and Matsuzawa Y: Peroxisome
proliferator-activated receptor gamma reduces the growth rate of
pancreatic cancer cells through the reduction of cyclin D1. Life
Sci. 70:1565–1575. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kawa S, Nikaido T, Unno H, Usuda N,
Nakayama K and Kiyosawa K: Growth inhibition and differentiation of
pancreatic cancer cell lines by PPAR gamma ligand troglitazone.
Pancreas. 24:1–7. 2002. View Article : Google Scholar
|
|
20
|
Itami A, Watanabe G, Shimada Y, Hashimoto
Y, Kawamura J, Kato M, Hosotani R and Imamura M: Ligands for
peroxisome proliferator-activated receptor gamma inhibit growth of
pancreatic cancers both in vitro and in vivo. Int J Cancer.
94:370–376. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu J, Shen B, Chu ES, Teoh N, Cheung KF,
Wu CW, Wang S, Lam CN, Feng H, Zhao J, et al: Inhibitory role of
peroxisome proliferator-activated receptor gamma in
hepatocarcinogenesis in mice and in vitro. Hepatology.
51:2008–2019. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gomez DE, Alonso DF, Yoshiji H and
Thorgeirsson UP: Tissue inhibitors of metalloproteinases:
Structure, regulation and biological functions. Eur J Cell Biol.
74:111–122. 1997.PubMed/NCBI
|
|
23
|
Iki K, Takeo T, Kubozoe T, Aoki S, Hayashi
J and Tsunoda T: Detection of serum MMPs in tumor-bearing hamsters.
J Hepatobiliary Pancreat Surg. 9:478–484. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagakawa Y, Aoki T, Kasuya K, Tsuchida A
and Koyanagi Y: Histologic features of venous invasion, expression
of vascular endothelial growth factor and matrix
metalloproteinase-2 and matrix metalloproteinase-9 and the relation
with liver metastasis in pancreatic cancer. Pancreas. 24:169–178.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jones G, Machado J Jr, Tolnay M and Merlo
A: PTEN-independent induction of caspase-mediated cell death and
reduced invasion by the focal adhesion targeting domain (FAT) in
human astrocytic brain tumors which highly express focal adhesion
kinase (FAK). Cancer Res. 61:5688–5691. 2001.PubMed/NCBI
|
|
26
|
Galli A, Ceni E, Crabb DW, Mello T,
Salzano R, Grappone C, Milani S, Surrenti E, Surrenti C and Casini
A: Antidiabetic thiazolidinediones inhibit invasiveness of
pancreatic cancer cells via PPARgamma independent mechanisms. Gut.
53:1688–1697. 2004. View Article : Google Scholar : PubMed/NCBI
|
